What are the most valuable biotechnology startups?

Top startups in the Biotechnology market ranked by valuation

Here is an updated table that ranks the top startups in the Biotechnology market based on their latest reported or estimated valuations.

If you need to dig deeper and get more detailed data, please check our report covering the Biotechnology market.

What are the most valuable biotechnology startups today?

The most valuable biotechnology companies in this ranking are clustered between roughly $4 billion and $9 billion, with Caris Life Sciences holding the highest directly observable valuation at about $8.9 billion.

What stands out is how different these companies are. Caris is built around precision-oncology testing and molecular data. CG Oncology develops a bladder-cancer therapy. GRAIL sells a multi-cancer blood test. Parabilis Medicines is developing medicines against hard-to-drug proteins. Insilico Medicine and XtalPi come from the AI drug-discovery wave. Altos Labs is making a much longer-term bet on cellular rejuvenation.

That mix makes the top of biotech very different from markets where one business model clearly wins. Oncology is heavily represented, but there is no single technology behind the largest valuations.

Company	Valuation used	Main business	Valuation basis
Caris Life Sciences	≈$8.9B	Precision oncology	Public market
Altos Labs	$6B–$9B	Cellular rejuvenation	Estimated private value
CG Oncology	≈$6B–$7B	Bladder-cancer therapy	Public market
Stemcentrx	$5.8B	Cancer therapeutics	Acquisition value
Samsung Bioepis	$5.2B–$6B	Biosimilars	Estimated value
GRAIL	≈$4B–$5B	Multi-cancer detection	Public market
Parabilis Medicines	≈$4.1B	Protein-targeted medicines	Public market
Insilico Medicine	≈$4.7B	AI drug discovery	Public market
MGI Tech	≈$4.6B	Genomic sequencing	Public market
Shanghai Henlius Biotech	≈$4.4B	Biologics	Public market

Is Caris Life Sciences really the most valuable biotechnology startup?

Caris Life Sciences has the strongest claim to the top spot today because its roughly $8.9 billion valuation comes from a live public market rather than an old private funding round or a modelled estimate.

Caris has also given investors something many high-valued biotech companies still lack: a large, growing business. The company reported $263.7 million of second-quarter revenue, up 45% year over year, and lifted full-year revenue guidance to $1.03 billion to $1.04 billion. A diagnostics company with real revenue is a different business from a pre-revenue drug developer, and we compare which models make money in our report on biotech.

The operating numbers make the valuation easier to understand. Caris completed about 59,200 clinical cases during the quarter, up 18%, while molecular-profiling revenue rose 55%. Gross margin reached 68%, compared with 63% a year earlier. The quarterly net loss was just $0.6 million, down from $71.8 million.

Caris was already a large company when it went public. Its IPO implied a market value of roughly $6 billion, and the current value is about 50% above that level.

Is Altos Labs still the most valuable private biotech company?

Altos Labs is still one of the strongest candidates for the world's most valuable private biotech, although its exact valuation remains difficult to pin down.

Altos started life with an extraordinary amount of capital. The cellular-rejuvenation company launched with about $3 billion committed by investors, a financing base that most biotech startups would take many rounds to build.

Our current valuation range of roughly $6 billion to $9 billion reflects that funding base, the scientific team Altos assembled and the valuations attached to other heavily funded platform companies. What Altos does not have is a recent disclosed financing price that fixes the valuation precisely.

Isomorphic Labs has made the comparison harder lately. The Alphabet-backed company raised $2.1 billion in a Series B this year after an earlier $600 million external round. Xaira Therapeutics launched with more than $1 billion, while Kriya Therapeutics has raised close to $1 billion.

Altos remains near the front of private biotech by any reasonable measure, but without a fresh priced round the number stays uncertain.

How many biotechnology companies are worth more than $1 billion, and how rare is a $5 billion valuation?

More than 40 companies in our dataset are clearly worth at least $1 billion, while only a small handful can currently support a valuation above $5 billion.

A $1 billion valuation can come from a strong venture round, an IPO, several promising clinical programs or one unusually valuable asset. Crossing $5 billion generally requires much more. Caris has more than $1 billion of expected annual revenue. CG Oncology has enjoyed a huge public-market revaluation. Stemcentrx reached $5.8 billion through an acquisition. Altos has one of the largest private funding bases ever assembled in biotech.

There are also companies around the $1 billion line where the classification depends on the estimate. AltruBio sits around $900 million to $1.4 billion in our work. AvenCell falls roughly between $800 million and $1.3 billion. Karius ranges from around $750 million to $1.1 billion.

Valuation level	Rough number in our dataset	What it usually takes
$100M+	80+	Funded platform or clinical program
$500M+	60+	Strong financing or meaningful pipeline
$1B+	40+	Unicorn-scale private or public value
$2B+	25+	Major platform, clinical asset or public re-rating
$3B+	Around 15	Strong late-stage or platform conviction
$5B+	Fewer than 10	Exceptional commercial or strategic value
$8B+	Very few	Top end of the current market

Why do cancer biotech companies get such high valuations?

Cancer remains the clearest path to a very large biotech valuation because successful oncology assets can address huge markets and attract pharmaceutical buyers willing to spend several billion dollars.

The pattern runs through the ranking. Caris is a precision-oncology company. CG Oncology is developing cretostimogene for bladder cancer. Stemcentrx was bought for its cancer pipeline. Parabilis has oncology programs. RayzeBio developed radiopharmaceutical cancer therapies. Bicara, ArriVent, Vividion, TORL, Obsidian and Frontier Medicines add more oncology exposure further down.

Acquisition prices show how valuable a convincing cancer asset can become. Bristol Myers Squibb paid about $4.1 billion for RayzeBio. AbbVie paid $5.8 billion upfront for Stemcentrx. Bayer paid $1.5 billion upfront for Vividion, with another $500 million available through milestones. Prices like these show which cancer assets buyers will pay for, and we follow what investors back and what they avoid in our biotech market report.

Clinical data can change the value of an oncology company just as quickly. CG Oncology went public at $19 per share in 2024 and raised $437 million gross. Its market capitalization at listing was around $1.2 billion and is now above $6 billion.

Is AI drug discovery really worth billions already?

AI drug discovery has become a genuine multibillion-dollar biotech category, but the valuations are still ahead of the clinical proof.

Insilico Medicine is valued around $4.7 billion in our dataset. XtalPi has reached a multibillion-dollar public valuation. Isomorphic Labs has raised roughly $2.7 billion externally. Xaira Therapeutics started with more than $1 billion of backing. insitro sits in the low-single-digit billions in our estimate, while Formation Bio, Valo Health and Owkin form another group around or above the $1 billion level.

Isomorphic's recent $2.1 billion round shows how far investor conviction has moved. One private financing was larger than the entire lifetime funding of most biotechnology companies.

Investors are paying for more than individual molecules. The bet is that proprietary biological data, machine-learning models and automated experiments can create better drugs repeatedly.

The technological progress is real. AlphaFold changed what researchers can do with protein structures. Isomorphic is moving its own programs toward the clinic. Insilico has advanced AI-generated drug candidates into human testing. XtalPi combines computational work with automated laboratories.

The hard part has not disappeared. Better molecule design does not remove toxicology, manufacturing, patient recruitment, clinical endpoints or regulators. BenevolentAI's collapse in valuation and Exscientia's eventual combination with Recursion are reminders that impressive AI technology does not automatically produce successful medicines.

The multibillion-dollar valuations are real, but they still assume a future where AI improves drug development much more reliably than it has proved so far.

AI biotech	Valuation used in our ranking	Funding evidence	Main focus
Insilico Medicine	≈$4.7B	≈$817M	AI drug discovery
XtalPi	≈$3.8B+	≈$784M	AI and automated labs
Isomorphic Labs	Multibillion range	≈$2.7B	AI drug design
Xaira Therapeutics	$3B–$4B	$1B+	AI therapeutics
insitro	$2.3B–$3.3B	≈$643M	ML drug discovery
Valo Health	$2.4B–$3.2B	≈$400M	Data-driven drug discovery
Formation Bio	$1.6B–$2.4B	≈$610M	AI clinical development
Owkin	$0.9B–$1.2B	≈$304M	AI drugs and diagnostics

Are obesity biotech startups becoming the next valuation leaders?

Obesity has become one of the hottest areas in biotech valuation, although it still has fewer multibillion-dollar startups than oncology.

Eli Lilly and Novo Nordisk have shown that obesity drugs can become enormous commercial products. That immediately raised the potential value of any startup with a credible next-generation candidate.

Roche's acquisition of Carmot Therapeutics made the new economics visible. Roche agreed to pay $2.7 billion upfront, with another $400 million tied to milestones, for a portfolio led by the GLP-1/GIP agonist CT-388.

Kailera Therapeutics then launched with a $400 million Series A, unusually large for a new company. Its portfolio included injectable and oral obesity programs, including KAI-9531. Kailera has since reached the public market, where its valuation has moved into the billion-dollar range.

Competition is much tougher now. New obesity companies increasingly need oral dosing, better tolerability, muscle preservation, longer dosing intervals or a mechanism that can outperform the first wave of incretin drugs.

Can cancer-testing companies really be worth as much as drug developers?

Cancer diagnostics can absolutely reach multibillion-dollar valuations, and Caris Life Sciences and GRAIL show two very different ways to get there.

Caris already has a substantial commercial business. The company expects more than $1 billion of revenue this year, driven mainly by molecular profiling that helps doctors match cancer patients with therapies.

GRAIL is much more dependent on what happens next. Its Galleri blood test tries to detect multiple cancers before symptoms appear. If multi-cancer early detection eventually becomes routine screening, the addressable population could be enormous. Whether multi-cancer blood tests can become routine screening is the kind of technology question we sort from proven to on paper in our report on biotech.

The risk is equally large because screening healthy people requires unusually strong evidence. GRAIL shares have moved sharply around clinical and regulatory news. Earlier this year, the stock fell after a major UK trial missed its primary endpoint, then rebounded as Galleri moved closer to an FDA decision.

Caris is valued around a large oncology-testing business that already exists, while GRAIL still depends much more heavily on what cancer screening could become.

Are cell and gene therapy startups still worth billions?

Cell and gene therapy can still produce billion-dollar biotech companies, but investors are much pickier now about which approaches deserve that price.

ElevateBio sits above $2 billion in our estimates. Capstan Therapeutics reached as much as $2.1 billion in AbbVie's acquisition. Orna Therapeutics sits around $1.5 billion to $2.4 billion. Cellares recently reached roughly $1.4 billion. eGenesis can also reach the billion-dollar range depending on the valuation method.

The newer winners often attack the ugly operational parts of advanced therapy. Capstan works on programming cells inside the body. Cellares automates cell-therapy manufacturing. Orna is developing circular RNA. eGenesis is using gene editing to make pig organs more compatible with human transplantation.

Conventional cell therapy can be medically impressive while remaining expensive and difficult to manufacture, so investors are paying heavily for technologies that could make these treatments easier to deliver at scale.

Does raising $1 billion make a biotech company valuable?

Raising huge amounts of money does not guarantee a huge biotech valuation, and some of the biggest funding rounds in our dataset eventually produced severe value destruction.

CG Oncology shows the positive extreme. The company has raised hundreds of millions of dollars, yet its equity value has grown above $6 billion as investors became more confident in its clinical program.

Caris has also created much more equity value than the amount of capital historically invested into the company. The same broad pattern appears at XtalPi.

The reverse can be brutal. Eikon Therapeutics has raised more than $1 billion while its public value has fallen below that amount. Neumora Therapeutics has raised more than $600 million and has traded at a small fraction of its historical funding. Metagenomi has also fallen far below the amount investors put into the company.

Intarcia is the extreme historical case in our dataset. Roughly $1.5 billion was raised over its life, yet the residual business ended up worth only a tiny fraction of that.

The reason is specific to biotech: the money is spent proving whether drugs work. A failed trial can wipe out most of a company's expected future value even after years of expensive research.

Company	Funding in dataset	Current / final valuation	Approximate relationship
Caris Life Sciences	≈$1.86B	≈$8.9B	Value far above funding
CG Oncology	Hundreds of millions	>$6B	Value far above funding
XtalPi	≈$784M	≈$3.8B	Value well above funding
ElevateBio	≈$1.25B	$2.1B–$2.8B	Value above funding
Eikon Therapeutics	>$1.1B	<$1B	Value below funding
Neumora Therapeutics	≈$612M	≈$100M–$200M	Large value destruction
Metagenomi	≈$376M	Tens of millions	Large value destruction
Intarcia Therapeutics	≈$1.5B	Residual value only	Extreme value destruction

Which biotech IPOs have created the most value?

CG Oncology is one of the clearest recent biotech IPO winners, with its market capitalization rising from roughly $1.2 billion at listing to more than $6 billion.

CG Oncology sold shares at $19 in its 2024 IPO and raised $437 million gross. Its public value has since increased by roughly five times from the initial market capitalization.

Caris has also created substantial value after listing. The company went public with an initial market capitalization around $6 billion and is now worth close to $9 billion.

Maze Therapeutics listed at $16 per share and later traded above $40 before settling lower. Zenas BioPharma also moved well above its IPO reference value after pricing shares at $17.

Parabilis Medicines is one of the freshest examples. The company priced its IPO at $20 per share and initially entered the public market at roughly $2.4 billion. Its capitalization has recently been around $4 billion, after briefly moving above $5 billion.

Company	Approx. value around IPO	Recent valuation range	Direction
CG Oncology	≈$1.2B	>$6B	Very large increase
Caris Life Sciences	≈$6B	≈$8.9B	Strong increase
Parabilis Medicines	≈$2.4B	≈$4.1B	Strong increase
Zenas BioPharma	<$1B	≈$2B	Strong increase
Maze Therapeutics	<$1B	≈$1B+	Increase
Kailera Therapeutics	IPO-stage valuation	≈$1B+	Still developing
GRAIL	Low post-spin reference	Multi-billion today	Very large re-rating

Is the biotech IPO market really back?

The biotech IPO market is clearly healthier now, and the amount of capital raised already makes this more than a tiny rebound.

J.P. Morgan counted 13 biopharma IPOs raising about $5 billion during the first half of this year. That amount was already higher than the full-year IPO total in every year from 2022 through 2025. Whether the IPO window is really reopening is one of the market signals we track every quarter in our biotech market report.

Parabilis alone raised $670 million through its upsized IPO before counting the underwriters' option. Kailera sold $625 million of shares in its IPO.

Venture markets improved at the same time. BioPharma Dive counted at least 68 biotech startups raising more than $9.1 billion during the first six months among the investor groups it tracks. J.P. Morgan's broader biopharma dataset put first-half venture funding at $16.3 billion across 235 rounds.

The recovery is selective. BioPharma Dive found that most of the companies raising large rounds already had drugs in clinical testing.

Are Big Pharma acquisitions pushing biotech valuations higher?

Big Pharma acquisitions are giving biotech investors powerful reference prices, particularly in oncology, obesity and newer therapeutic platforms.

RayzeBio is a clean example. Bristol Myers Squibb agreed to pay about $4.1 billion for the radiopharmaceutical company. Roche paid $2.7 billion upfront for Carmot Therapeutics. AbbVie agreed to pay up to $2.1 billion in cash at closing for Capstan Therapeutics. Bayer paid $1.5 billion upfront for Vividion.

Those deals give private investors concrete comparable prices. A $1 billion private valuation looks much easier to defend when pharmaceutical buyers have recently paid $2 billion to $4 billion for similar assets.

Current deal volume reinforces that effect. J.P. Morgan counted $96 billion of biopharma M&A across 80 transactions during the first half of this year.

Which private biotech companies could break into the top 10?

Isomorphic Labs has the clearest path into the top valuation tier among today's private biotech companies because investors have just committed another $2.1 billion to its AI drug-design platform.

That round was led by Thrive Capital and included Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The company plans to use the capital to scale its AI drug-design engine and move its own therapeutic pipeline toward the clinic.

Xaira Therapeutics is another obvious candidate. The company launched with more than $1 billion and an unusually experienced scientific team. Kriya Therapeutics has raised close to $1 billion. Mirador Therapeutics launched with more than $400 million and a team drawn heavily from Prometheus Biosciences. Cellares has also moved into the billion-dollar group as cell-therapy manufacturers look for ways to automate production.

Clinical evidence will decide which of them can turn that funding scale into a $5 billion-plus valuation.

Is the biotech winter over?

The biotech winter is easing quickly, although the recovery is concentrated in companies that already have something investors can evaluate.

J.P. Morgan counted $16.3 billion of first-half biopharma venture funding, $5 billion raised through 13 IPOs and $96 billion of M&A. BioPharma Dive also found that venture-backed biotech startups had their strongest first half since 2022 within the group it tracks.

Public markets have produced big winners at the same time. CG Oncology has multiplied in value since its IPO. Caris is worth substantially more than at listing. Parabilis quickly moved above its IPO valuation.

The filter is pretty clear. Investors are concentrating money in companies with clinical data, established programs, differentiated technology or serious commercial traction. Early science with little human evidence is still much harder to fund.

What does the biotechnology startup valuation ranking tell us right now?

Biotechnology has clearly returned to multibillion-dollar valuation territory, but today's market rewards evidence far more aggressively than it rewards a good scientific story on its own.

Caris gives us the strongest observed valuation at roughly $9 billion and backs it with more than $1 billion of expected annual revenue. CG Oncology shows how quickly convincing clinical progress can turn a roughly $1 billion IPO company into a $6 billion-plus business. Altos Labs and Isomorphic Labs show that investors will still commit enormous amounts of private capital when they believe a platform could create a new class of drugs. Clinical progress that lifts a $1 billion company to $6 billion is one of the growth drivers we break down in our market report about biotech.

Oncology remains the most reliable source of large valuations. AI drug discovery has joined the top tier before fully proving its clinical economics. Obesity has become one of the most competitive areas for new capital. Diagnostics can also reach several billion dollars when the addressable market is large enough.

At the other end, companies that raised $500 million, $1 billion or more have sometimes lost most of their value. Funding alone tells us surprisingly little about what a biotech company is worth today.